New Delhi:A group of American scientists has found a new possibility to cure leukemia, a deadly disease that strikes patients as young as seven.
In a study published in the Journal Nature Medicine, the group from Stanford University and National Institute of Health (NIH) found that a molecule, called CD22, can serve as a potent target for the killer cells of acute lymphoblastic leukemia.
The development comes after the US Food and Drug Administration last year approved a cell-based gene therapy called the CAR T-cell treatment.
It works by genetically modifying a patient’s own immune cells to seek out and attack leukemia cells that have a molecule called CD19 on their surface.
Stanford oncologist Crystal Mackall and NIH’s pediatric haematologist Terry Fry, discovered that a molecule called CD22 can be a similar target.
Scientists treated 21 patients with treatment-resistant B-cell leukemia who are aged seven to 30 to test the new CD22-directed method.